Gallium-68-THP PSMA

Drug Profile

Gallium-68-THP PSMA

Alternative Names: 68Ga-THP-PSMA; Ga-68-THP-PSMA; Gallium-68 tris-hydroxypyridinone prostate specific membrane antigen

Latest Information Update: 05 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Peter MacCallum Cancer Centre
  • Class Diagnostic agents; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase 0 Prostate cancer

Most Recent Events

  • 01 Feb 2017 Peter MacCallum Cancer Centre completes a phase 0 trial in Prostate cancer (Diagnosis, In adults, In the elderly) in Australia (IV) (ACTRN12615001324505)
  • 01 Nov 2016 Interim adverse events and pharmacodynamics data from a phase 0 trial in Prostate cancer (Diagnosis) released by Theragnostics and Peter MacCallum Cancer Centre
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top